Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRII-179 in chronic hepatitis B
ACTRN12619001210167Phase 2Completed
- Sponsor
- Brii Biosciences
- Start
- Nov 2019
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
Phase 2, open-label trial of BRII-179 and interferon alfa in Chronic Hepatitis B (CHB) (5 cohorts), sponsored by Brii Biosciences. Primary endpoint: Number of subjects with adverse events. Started Nov 2019; status: completed.
02
Drugs
BRII-179interferon alfa
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ACTRN12619001210167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001210167.